Ultragenyx Pharmaceutical Inc. RARE
15.57 USD -1.59 (-9.27%)
At closeNov 5, 2026, 4:00 PM EST
15.30 -0.27 -1.73%
After hours · Nov 5, 4:00 PM ET
15.49 Day range 17.12
12.73 52-week range 39.89
- YTD
- -32.30%
- 1 year
- -51.15%
Analyst view
Consensus: buy
Buy
Price target (mean) 26.35 +69.2% upside
Now 15.57
- Target (low)
- 16.00
- Target (mean)
- 26.35
- Target (high)
- 39.00
Ratings (0m) 21 10 buy · 11 hold · 0 sell
- Strong buy2
- Buy8
- Hold11
- Sell0
- Strong sell0
Recommendation trend
- This month 21
- 1 month ago 21
- 2 months ago 20
- 3 months ago 20
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.66246 | -1.08 – 0.78 | -1.29 | +48.7% | 231.60M | +11.9% | 6 |
| Next quarter | -0.44 | -0.94 – 0.06 | -1.54 | +71.4% | 202.48M | +48.9% | 2 |
| Current year | -4.08 | -4.96 – -1.18 | -5.83 | +30.1% | 760.13M | +13.0% | 6 |
| Next year | 0.22559 | -1.69 – 4.50 | -4.08 | +105.5% | 997.92M | +31.3% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | TD Cowen | Maintained | Buy | Buy |
| Nov 4, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Nov 4, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Nov 4, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Nov 4, 2026 | Wedbush | Maintained | Neutral | Neutral |
| Oct 15, 2026 | UBS | Initiated | — | Neutral |
| Sep 21, 2026 | Evercore ISI Group | Maintained | In-Line | In-Line |
| Sep 21, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 18, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Sep 18, 2026 | Citigroup | Maintained | Buy | Buy |
| Sep 18, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Sep 18, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Sep 17, 2026 | Citigroup | Maintained | Buy | Buy |
| Sep 4, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Sep 4, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 3, 2026 | JP Morgan | Downgrade | Overweight | Neutral |
| Sep 3, 2026 | Jefferies | Maintained | Buy | Buy |
| Sep 3, 2026 | William Blair | Downgrade | Outperform | Market Perform |
| Sep 3, 2026 | Citigroup | Maintained | Buy | Buy |
| Sep 3, 2026 | TD Cowen | Maintained | Buy | Buy |
| Sep 3, 2026 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| Sep 3, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Sep 3, 2026 | Wedbush | Maintained | Neutral | Neutral |
| Sep 3, 2026 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| Sep 3, 2026 | Baird | Downgrade | Outperform | Neutral |
| Sep 3, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 3, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Aug 28, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 25, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 21, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |